Compare · BSX vs SOLV
BSX vs SOLV
Side-by-side comparison of Boston Scientific Corporation (BSX) and Solventum Corporation (SOLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SOLV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 5.1x SOLV ($14.03B).
- Over the past year, BSX is down 51.5% and SOLV is up 8.1% - SOLV leads by 59.6 points.
- SOLV has been more active in the news (16 items in the past 4 weeks vs 12 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 19 for SOLV).
- Company
- Boston Scientific Corporation
- Solventum Corporation
- Price
- $48.56-0.60%
- $81.01-1.72%
- Market cap
- $72.16B
- $14.03B
- 1M return
- -13.30%
- +14.11%
- 1Y return
- -51.46%
- +8.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2024
- News (4w)
- 12
- 16
- Recent ratings
- 25
- 19
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest SOLV
- Solventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form SD filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Solventum to Participate in the 2026 Jefferies Healthcare Conference
- Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Alban Carlos
- SEC Form 4 filed by Director Cox Carrie Smith
- SEC Form 4 filed by Director Devore Susan D.
- SEC Form 4 filed by Director Edwards Shirley Ann
- SEC Form 4 filed by Director Eisenberg Glenn A